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Abstract
Purpose of review—Co-infection with Plasmodium falciparum (Pf-) malaria and Epstein-Barr
virus (EBV) are implicated in the etiology of endemic Burkitt lymphoma (eBL), the most
prevalent pediatric cancer in equatorial Africa. Although the causal association between EBV and
eBL has been established, Pf-malaria’s role is not as clearly defined. This review focuses on how
malaria may disrupt EBV persistence and immunity.
Recent findings—Two mutually-compatible theories have been proposed. One suggests that Pf-
malaria induces polyclonal B-cell expansion and lytic EBV reactivation, leading to the expansion
of latently infected B-cells and the likelihood of c-myc translocation; a hallmark of BL tumors.
The other advocates that EBV-specific T-cell immunity is impaired during Pf-malaria co-
infection, either as a cause or consequence of enhanced EBV replication, leading to loss of viral
control. Advancements in our ability to query the complexity of human responses to infectious
diseases have stimulated interest in eBL pathogenesis.
Summary—EBV is necessary but not sufficient to cause eBL. A more dynamic model
encompasses incremental contributions from both chronic and acute Pf-malaria leading to
alterations in EBV persistence and EBV-specific immunity that culminate in eBL. A better
understanding of how Pf-malaria modifies EBV infections in children may allow us to anticipate
reductions in eBL incidence coinciding with malaria control programs.
Keywords
Malaria; EBV; endemic Burkitt lymphoma; T-cell immunity; B-cell immunity
Introduction
In recent years meaningful decreases in malaria-associated morbidity and mortality have
been observed worldwide due to multi-factorial global efforts to control and prevent malaria
[1]. These campaigns have significantly decreased malaria in endemic areas however it is far
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from being eradicated. Malaria vaccine efforts are underway with lofty goals of not only
preventing disease but ideally preventing infections and transmission. After considerable
discussion about clinical endpoints for malaria vaccine efficacy trials, decreases in malaria-
associated mortality and morbidity would be acceptable short-term until a vaccine is
designed that prevents infection. Thus the possibility exists that a vaccine (or other
intervention) which prevents clinical malaria yet does not prevent infections might create a
carrier state whereby children harbor untreated infections. One could argue that
asymptomatic malaria infections are beneficial and induce naturally acquired protective
immunity [2**]. Conversely, chronic malaria infections may have detrimental effects
contributing to anemia [3] or malaria-associated diseases such as endemic Burkitt lymphoma
(eBL) [4].
Endemic BL has long been associated with early-age Epstein Barr Virus (EBV) infection
and geographically linked to holoendemic Plasmodium falciparum (Pf)-malaria [4,5].
Several key observations have established a causal role for EBV in eBL tumorigenesis. EBV
was first isolated from and subsequently found in nearly 100% of eBL tumors [6,7]. EBV
sero-surveys concluded that children in developing countries experience their primary
infection before the age of 3 years [8]. And significantly elevated antibody titers to EBV
viral capsid antigen (VCA) were found in children who later went on to develop eBL [9].
Since these seminal observations, the role of EBV as a tumor virus and EBV-specific T-cell
immune control has been extensively explored [10,11]. In comparison, this review focuses
on the role Pf-malaria plays eBL pathogenesis.
There are two prevailing, though not mutually exclusive theories to explain the relationship
between EBV and Pf-malaria in eBL etiology [12]. One suggests that Pf-malaria induces
polyclonal B-cell expansion and consequently lytic EBV reactivation, thus leading to the
expansion of latently infected B-cells and the likelihood of c-myc translocation, which is a
hallmark of all BL tumors. The other theory argues that EBV-specific T-cell immunity is
selectively impaired during Pf-malaria co-infection, either as a cause or consequence of
enhanced EBV replication, leading to loss of viral control. Our growing appreciation for the
complexity of human immunity allows us to delve further into the question of how Pf-
malaria contributes to EBV de-regulation.
Epidemiologic studies to evaluate the role for Pf-malaria in eBL
Whereas the causal association between EBV and eBL has been established, Pf-malaria’s
role in eBL pathogenesis is not as well understood. Holoendemic malaria is characterized by
intense perennial transmission with the highest morbidity and mortality in children under the
age of 5 years. Under such conditions, infants and young children are repeatedly infected
with Pf-malaria, can harbor chronic asymptomatic often untreated infections. Recurrent
infections engender partial immunity to Pf-malaria which allow sustained often high density
infections [2]. Since both chronic and acute Pf-malaria infections are common in children
residing in holoendemic areas, deconvoluting the multiple opportunities malaria has to
influence EBV persistence is challenging.
Anti-malarial treatment in holoendemic area has been associated with a decrease in eBL
incidence [13,14] although few studies have directly addressed the causality. A historical
‘malaria-suppression’ trial was conducted in Tanzania from 1977 to 1982 in an area
monitoring eBL and malaria prevalence [15]. This intervention study distributed chloroquine
to ~100,000 children below 10 years of age every two weeks for five years in an explicit
attempt to reduce eBL incidence. They observed a decrease in eBL but could not conclude
that treating malaria was the sole mediator because eBL incidence had been declining prior
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to the study. However, the prevalence of malaria cases also declined prior to the intervention
mirroring the decline in eBL incidence.
Other attempts to determine if relative peaks in malaria act as a ‘trigger’ of eBL by
analyzing space-time clustering or seasonality of cases were also inconclusive [16].
However using spatial analytical models, significant high-risk clusters for eBL incidence
were found within a malaria holoendemic region thereby highlighting the heterogeneity of
individual-malaria exposure within holoendemic areas [17]. In addition, though the
incidence of eBL is significantly lower in areas with hypoendemic malaria, eBL may still
occur [18,19]. These observations support the premise that timing of co-infection and
duration of Pf-malaria infections on an individual-level is critical for understanding the
dysregulation of EBV leading to eBL.
The coincidence of Pf-malaria infection preceding eBL further supports a temporal
interaction with EBV. The average age of eBL patients in malarious areas was noted to be
8.1 years while in low risk malarious areas it was 16.2 years [20]. In addition, immigrants
from malaria hypoendemic areas who moved to holoendemic areas presented with eBL in
late adolescents and adulthood [20]. A similar pattern was also found as most adult cases of
eBL were born in hypoendemic areas [21]. Figure 1 depicts the chronology of EBV and Pf-
malaria co-infections in relation to eBL incidence in malaria holoendemic areas. The peak
age-related incidence of eBL is 4-9 years of age [19,20], after the age at which Pf-malaria-
associated morbidity, mortality and parasite densities are the highest. Even though these
children experience their primary EBV infection before three years of life [8] it is extremely
rare for a child to develop eBL before two years of age suggesting a prolonged interaction is
necessary for these co-infections to promote tumorigenesis. In support of this, the Tanzanian
study [15] reported a two-year lag between Pf-malaria burden and eBL incidence with a
concomitant increase in eBL incidence after the intervention was stopped. BL is one of the
most rapidly dividing human tumors [10], thus the eBL ‘triggering event’ must occur
proximal to tumorigenesis. Malaria and EBV co-infections are common in children residing
in high-risk eBL areas, although the incidence of eBL is only 1-5 per 100,000 children
annually. Pf-malaria may play multiple roles in eBL pathogenesis whereby co-infection
during primary EBV infection sets the stage for deregulation of EBV latency and repeat
malaria infections exacerbates EBV homeostasis and T-cell immunity.
EBV-specific T-cell immune deregulation by Pf-malaria
Based on other studies of acute infectious mononucleosis and healthy EBV seropositive
adults, we know that EBV-specific T-cells restrict viral replication and limit the number of
latently infected B-cells [22]. Thus, EBV load in peripheral blood has been used as surrogate
measure for loss of T-cell mediated viral control [23]. The first study to measure EBV load
in children living in a malaria holoendemic area found the youngest children had
significantly higher EBV loads compared to older children, adults and children from a
hypoendemic area [24]. Ensuing studies measured EBV before and after episodes of acute
clinical malaria and even though viremia was consistently higher in acute cases than
controls, changes in viral load resulting from an episode of acute malaria could not be
consistently measured after the episode resolved [24-28]. These contradictory findings could
be the results of differences in cumulative Pf-malaria exposure and the frequency of latently
infected B-cells present. A recent study using multi-level mixed modeling found that
children residing in a malaria holoendemic area experienced their primary EBV infection
significantly earlier compared to children from a hypoendemic area and that individual
malaria burden over time were significant predictors of higher EBV viral load (Rochford,
unpublished data). These findings highlight the need for prospective studies designed to
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measure individual-level exposure to both Pf-malaria and EBV in order to understand how
the heterogeneity in timing and intensity of these co-infections interact.
In immune competent individuals, EBV persistence is an elegant balance between viral
immune evasion strategies and regulation mediated by CD8+ and CD4+ T-cells specific to a
hierarchy of latent and lytic EBV antigens [23*,29]. The notion that Pf-malaria interferes
with immunological control over EBV occurred early on [30] even before studies directly
assessing the impact of malaria on EBV-specific T-cell function were conducted. These
seminal studies measured in vitro regression of EBV-induced B-cell transformation and
concluded that acute malaria infection and chronic malaria exposure resulted in loss of
EBV-specific T-cell immunity [31-33]. This assay measured T-cell immunity against latent
but not lytic cycle antigens [34] and were not compared to T-cell responses to Pf-malaria
antigens or other measurements of global immune competence.
A more recent study measured EBV-specificity and function by IFN-γ ELISPOT,
concluding that children 5-9 years of age, after recurrent Pf-malaria infections, had impaired
response to both lytic and latent EBV CD8+ T-cell epitope-peptides compared to children
from a hypoendemic area [35]. A transient impairment of IFN-γ ELISPOT recall responses
around an episode of acute Pf-malaria was consistent with earlier regression studies.
However the decrease in T-cell immunity did not accompany a concomitant increase in EBV
load, although viremia remained significantly higher in Pf-malaria cases compared to
healthy controls even though T-cell responses were restored to normal levels [26]. It is
possible that this loss of EBV-specific T-cells in the peripheral circulation was due to T-cell
trafficking to the site of EBV replication during acute infection. A third study examined the
duration of IFN-γ ELISPOT recall responses over a 2-year period using both an ecologic
and individual-level definition for Pf-malaria exposure and found that T-cell responses
gradually diminished to EBV lytic but not latent antigens in 5-9 year old malaria-exposed
children compared to other age groups and non-malaria exposed children (Snider and
Moormann, unpublished data). In contrast, IFN-γ recall responses to EBV lytic and latent
antigens in children diagnosed with eBL were robust; however, the effector cell secreting
IFN-γ cannot be identified by ELISPOT [36**]. Table 1 summarizes relevant studies
directly investigating the impact of Pf-malaria on immunity to EBV.
Advancements in polychromatic flow cytometry have enabled us to learn more about human
T-cell differentiation and function [37] and EBV-specific T-cell phenotypes, especially
when blood sample volumes are limited. Using a 16- parameter flow cytometry panel
developed to quantify differentiation, exhaustion, senescence and homeostatic potential for
EBV-specific CD8+ T-cell restricted by HLA A*0201to epitopes derived from latently-
expressed and lytic phase proteins, we found that individuals residing in a malaria
holoendemic area have significantly more differentiated EBV-specific CD8+ T-cells
compared to those residing in a hypoendemic area and this profile shift was strongest for
responses to EBV latent antigens (Moormann, Price and Chattopadhyay unpublished data).
Taken together, these studies suggest that Pf-malaria co-infections during the establishment
of EBV-latency may negatively impact EBV-latent antigen specific T-cell lineage
commitment and that recurrent Pf-malaria infections over time diminish the functional
capacity of EBV-lytic antigen-specific T-cells.
Malaria’s influence on B-cells (where EBV latently resides)
The development of humoral immunity is important for mediating protection against Pf-
malaria, yet identifying which antibodies confer protection given the plethora of
immunogenic parasite antigens remains enigmatic [2]. Sero-prevalence to malaria antigens
by the age at which a child is at risk for eBL reflects cumulative lifetime exposure and could
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be used to infer differences in transmission intensity when comparing populations. The
caveat to applying single Pf-malarial antibody titers as a surrogate for the number or severity
of past Pf-malaria infections is they are not quantitative and depend on the immunogenicity
of the malaria antigen and the longevity of the antibody response being measured [38-40].
Antibodies also play a role in limiting EBV infection and reflect the clinical status of the
individual [41]. During primary EBV infection, immunoglobulin (Ig) M to VCA appears
first, followed by VCA IgG that persists through life. Epstein Barr nuclear antigen (EBNA1)
IgG is detectable 2-4 months after infection and remains throughout life. The Z
transactivation antigen (ZEBRA or Zta) is an immediate early protein indicative of EBV
replication and signifies the switch from latent to lytic replication [42*]. Elevated VCA IgG
antibody levels have been associated with eBL incidence [9]. A recent study found elevated
anti-ZEBRA and anti-VCA levels in eBL patients compared to healthy children, and
elevated ZEBRA antibodies were associated with higher EBV load in eBL children [43**].
However, there is no consensus on the cumulative effect of Pf-malaria on EBV antibody
titers in otherwise healthy children. A number of early studies on acute Pf-malaria found no
difference in anti-VCA titers during and after Pf-malaria infection or among residents of
different malaria transmission areas [44,45]. Another study on acute Pf-malaria reported that
ZEBRA IgG levels were significantly higher among children infected with Pf-malaria
compared to controls [25]. The only study to examine the effect of chronic Pf-malaria on
EBV antibody titers found higher IgG titers to EBNA1, VCA, and ZEBRA in children from
a malaria holoendemic area compared to children from a hypoendemic area [46**].
Meanwhile, a significant decrease in IgG titers for all EBV antigens with increasing age was
observed in children from the hypoendemic area [46**]. These observations suggest that
antibody titers may be useful to monitor cumulative EBV latency and lytic reactivation but
are not supple enough to directly measure the influence of Pf-malaria on EBV-infected B
cells.
Pf-malaria has been shown to be a powerful B-cell mitogen inducing hypergamma-
globulinemia [47-49]. The cysteine-rich interdomain region 1α (CIDR1α) domain of the Pf
erythrocyte membrane protein 1 (PfEMP1) has been shown in vitro to activate proliferation
of B-cells from individuals with no previous malaria exposure, preferentially targeting
activation of memory B-cells, and providing protection against apoptosis [50]. A direct link
between CIDR1α and EBV-infected B-cells has also been demonstrated suggesting
CIDR1α could trigger reactivation of EBV during Pf-malaria infection [51]. Directly testing
this interaction in vivo presents the obvious limitation for human studies, nonetheless the
possibility remains that chronic Pf-malaria stimulation could continue to reactivate latently
infected B-cells even in the absence of acute malaria infections.
More recent attention has focused on the generation of human B-cell memory subsets and
deciphering signals that determine if antibodies are secreted from long- or short-lived
plasma cells [52-54]. As an immune evasion strategy malaria appears to directly influence
B-cell differentiation by impeding the development of long-lived memory B-cells and
allowing the generation of atypical short-lived memory B-cells [55*,56]. Considering that
B-cells are where EBV persists, integrating the influence of EBV on the B-cell compartment
with signals from Pf-malaria poses choreographic challenges [57*]. Flow cytometry allows
the delineation of naïve B-cells into memory subsets. CD10 is a classical marker for
germinal center B-cells and eBL tumor cells [10]. However, CD10 is also expressed on
immature transitional B-cells present during chronic infection [58*]. In healthy EBV sero-
positive individuals, EBV is strictly cell-associated and found in the memory B-cell
compartment [10]. Children with acute clinical malaria are found to have a significantly
higher number of transitional B-cells in their peripheral circulation [59]; and this subset is
more susceptible to EBV infection compared to other memory B-cell subset and also
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expresses elevated levels of microRNA which is important in blocking B-cell differentiation
[60*]. Malaria-induced alterations in B-cell differentiation in conjunction with identifying
possible alternative EBV reservoirs has yet to be fully investigated.
Conclusion
There is still much to learn about the host orchestration of recurrent Pf-malaria infections
and EBV persistence that crescendo into eBL. Unexplored moderators of immunity include
innate immune signals, other lymphocyte subsets such as natural killer cells, gamma-delta T
cells and regulatory T cells. Exploring human genetic susceptibility for eBL necessitates
large DNA repositories linked with medical informatics than may shed new light on
etiologic pathways. Designing studies using a systems biology approach will allow us to
encompass the complexity and diversity of human immune responses to infectious diseases
whereby our understanding of eBL pathogenesis will achieve a new zenith.
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• Acute and chronic Pf-malaria infections may differentially impact T-cell
immunity to EBV latent and lytic antigens.
• A systems biology approach simultaneously measuring T-cell immune control
over EBV latency and lytic reactivation during acute and chronic Pf-malaria
infections will improve our understanding of eBL etiology.
• An improved understanding of the sequence of events shaped during Pf-malaria
and EBV co-infections will help target eBL prevention strategies.
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Figure 1. Chronology of Pf-malaria and EBV infections in relation to eBL incidence
Timing of co-infections prior to peak age-related incidence of eBL suggest a cumulative
interaction that results in the deterioration of immune control over EBV.
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Table 1






















1 Endemic (ie African) BL was identified as the only
tumor where EBV was consistently detected.
2 Pf-malaria proposed as a co-factor but mechanisms
unknown.
3 “Immunologic orchestra” to control EBV mediated by














1 Higher in vitro regression endpoints for adults from
holoendemic area compared to hypoendemic control
groups. No difference between two control groups.
2 Spontaneous transformation of B-cells in individuals













1 Higher in vitro regression indices during acute Pf-
malaria infection compared to convalescence.
2 During acute Pf-malaria infection, number and
proportion of T-helper cells was reduced.














1 Higher in vitro regression indices for acute Pf-malaria
cases than malaria-naïve controls.
2 Malaria cases had higher numbers of B-cells and
CD8+ T-cells; ratio of CD4:CD8 reduced compared to
controls.
3 Greater proportion of spontaneously transformed B-
















1 No difference in EBV-specific cytotoxic T-cell
responses measured by IFN-γ ELISPOT between two
groups of children.
2 When stratified by age group, children 5-9 years old
from malaria holoendemic area had significantly fewer
IFN-γ responses to EBV lytic and latent antigens
compared to other age groups and children from the
hypoendemic area.
3 Children from holoendemic area had significantly less
Interleukin-10 responses to EBV lytic peptides




















1 HLA-B*3501 restricted IFN-γ ELISPOT responses
were not significantly different between Gambian and
UK adults, though there was a trend for median EBV
lytic but not latent responses to be lower in Gambians.
2 Gambian children had fewer IFN-γ ELISPOTs to
pooled EBV lytic and latent antigens during acute Pf-
malaria infection compared to recovery levels and to




































1 First study to directly measure EBV-specific T cell
immunity in children diagnosed with eBL and
discovered that eBL children were deficient in IFN-γ
ELISPOT responses to EBNA1 (the sole EBV antigen
expressed by eBL tumor cells) but not EBV lytic and
latent CD8-epitope peptides.
2 eBL patients had IgG1 subclass antibodies to EBNA1,
similar to control groups suggesting loss of EBNA1-
specific Th1-polarized T cells.
3 Lack of IFN-γ ELISPOT to EBNA1 was associated















1 Using both a geographic and individual-level definition
of malaria exposure found a gradual decrease in EBV
lytic antigen but not latent antigen responses measured
by IFN-γ ELISPOT.
2 Children 5-9 years of age had significantly diminished
IFN-γ responses to EBV lytic but not latent antigens
associated with malaria exposure compared to other
age and malaria exposure groups.
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